Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 19/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6414927 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634498 | 0.82 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634030 | 0.79 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634712 | 0.78 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634250 | 0.76 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4634890 | 0.74 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634516 | 0.74 | SLC6A2 (0.82) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634194 | 0.74 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634825 | 0.74 | SLC6A2 (0.81) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 | |
| SCHEMBL4634072 | 0.73 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | claimed |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | SLC6A4 1/4885SLC6A2 7/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.